Corcept Therapeutics (CORT) Receivables - Net (2012 - 2026)

Corcept Therapeutics has reported Receivables - Net for 15 years, with the latest figure at $76.9 million in Q2 2026.

• Quarterly Receivables - Net rose 19.13% year-over-year to $76.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $76.9 million (up 19.13% YoY) and the FY2025 annual result came in at $59.8 million, up 10.76% from the prior year.
• Receivables - Net improved to $76.9 million in Q2 2026 per CORT's latest filing, from $39.1 million in the prior quarter.
• Over five years, Receivables - Net peaked at $76.9 million in Q2 2026 and troughed at $27.2 million in Q1 2022.
• A 5-year average of $47.6 million and a median of $47.5 million in 2023 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2024 and 2026: Receivables - Net jumped 88.95% in 2024, then sank 36.8% in 2026.
• Over 5 years, Receivables - Net stood at $31.1 million in 2022, then jumped by 32.41% to $41.1 million in 2023, then surged by 31.26% to $54.0 million in 2024, then grew by 10.76% to $59.8 million in 2025, then grew by 28.66% to $76.9 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $76.9 million, $39.1 million, and $59.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.